Concord Biotech Limited — Important, 26-07-2025: General Updates

Concord Biotech's Active Pharmaceutical Ingredient (API) facility in Dholka has successfully completed its Russian Good Manufacturing Practice (GMP) inspection. This crucial operational achievement underscores the company's commitment to global quality and regulatory compliance. This approval is a significant business development, potentially opening doors for enhanced market access and solidifying their presence in the Russian pharmaceutical landscape, reinforcing operational capabilities and investor confidence.